PrecivityAD2 is a blood test that the FDA cleared on August 20, 2026, to help diagnose Alzheimer's disease in adults aged 40 and older who show signs of cognitive impairment, a lower age floor than earlier cleared blood tests used (Alzheimer's Association). For families facing symptoms before age 65, that change opens a door to a faster, less invasive path toward answers. Alzheimer's Association president and CEO Joanne Pike said the extension to age 40 "recognizes that younger-onset Alzheimer's is a reality for many families" and can help more of them get clarity and start care planning sooner (Alzheimer's Association). The sections below lay out what the test actually measures, what its results mean, and what questions are worth bringing into a clinician's office.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What PrecivityAD2 Measures and Why That Matters for Younger Patients
- Why Younger-Onset Alzheimer's Is Often Missed in the First Place
- How Accurate Is the Test, and What Do "Positive" and "Negative" Actually Mean?
- Questions to Bring to a Clinician
- When and Where the Test Is Available
- Frequently Asked Questions
What PrecivityAD2 Measures and Why That Matters for Younger Patients
PrecivityAD2, made by C2N Diagnostics, uses mass spectrometry to measure two markers in a blood sample: plasma %p-tau217 and the amyloid-beta 42/40 ratio. An algorithm combines both to flag the likelihood of amyloid pathology, the buildup of a protein associated with Alzheimer's disease, according to NeurologyLive. The test is not a stand-alone diagnosis or a screening tool for people without symptoms.
C2N Diagnostics' own announcement states it is meant to be used alongside a full clinical evaluation by a clinician experienced in assessing cognitive impairment (C2N Diagnostics). That distinction matters for a younger-onset family: a positive or negative blood result is one input a clinician weighs alongside a history, a cognitive exam, and often other testing, not a verdict delivered on its own. Lowering the age floor to 40 is the practical change here. Earlier cleared blood tests for Alzheimer's were validated and labeled for older adults, which left a gap for anyone with symptoms well before the traditional late-onset age range.
Why Younger-Onset Alzheimer's Is Often Missed in the First Place
Younger-onset Alzheimer's, meaning onset before age 65, frequently looks different from the disease in older adults. Roughly one in three cases present with posterior cortical atrophy features, such as trouble recognizing objects or processing visual information, rather than the memory loss most people associate with Alzheimer's (Women's Brain Health Initiative). That mismatch between symptoms and expectations has consequences.
A published case series found that 53% of younger-onset patients with these atypical, non-memory symptoms were initially misdiagnosed with a psychiatric or other neurological condition, compared with just 4% of those who presented with classic memory problems, before the correct diagnosis was eventually made (NEJM Journal Watch). This history is the backdrop for why a blood test aimed at ages 40 and up matters. A tool that can point toward or away from amyloid pathology earlier in the diagnostic process may shorten the detour through other explanations, particularly for a patient whose symptoms don't fit the memory-first pattern clinicians are trained to look for first.
How Accurate Is the Test, and What Do "Positive" and "Negative" Actually Mean?
In C2N's clinical validation cohort of 1,142 subjects, results were checked against amyloid PET scans or spinal fluid testing, the reference standards for confirming amyloid pathology. A Positive PrecivityAD2 result carried a 97.6% positive predictive value, meaning it correctly matched confirmed amyloid pathology in that share of cases. A Negative result carried a 93.1% negative predictive value (CAP Today).
A third category complicates that otherwise strong performance. About 17.3% of the validation cohort fell into an intermediate "Likely Positive" result, which carried a lower 77.3% positive predictive value than a clean Positive (CAP Today). A result in that middle zone is less conclusive on its own and needs more weight given to the rest of the clinical picture, such as symptom history and cognitive testing, rather than being treated as a final answer. For a family walking into an appointment, this means the result category matters as much as the headline word "positive" or "negative." A Likely Positive result is a signal to ask what else the clinician is weighing, not a result to take at face value.
Questions to Bring to a Clinician
A younger-onset diagnosis touches work, finances, and family planning differently than a late-life diagnosis, so the questions worth asking go beyond the test itself. Consider raising these directly: Bringing a written symptom timeline to the appointment, including when non-memory symptoms started, helps a clinician match the picture against what's known about atypical younger-onset presentations.
- Is PrecivityAD2 appropriate given my specific symptoms, and will it be paired with a cognitive exam and clinical history, consistent with how C2N says it should be used (C2N Diagnostics)?
- Which result category did I receive: Positive, Likely Positive, or Negative, and what predictive value applies to that specific category (CAP Today)?
- If my symptoms are non-memory, such as vision or word-finding problems, has posterior cortical atrophy or another atypical presentation been considered (Women's Brain Health Initiative)?
- Has a psychiatric or other neurological explanation been ruled out, or only assumed, given how often that happens with atypical younger-onset cases (NEJM Journal Watch)?
- Where is this specific blood test available right now, through the clinician's own ordering process or through C2N's laboratory?
When and Where the Test Is Available
The FDA-cleared version of PrecivityAD2 is expected to reach broader clinical availability later in 2026. A CLIA-validated version of the same test has already been offered through C2N's own clinical laboratory (Healio). That gap between clearance and wide rollout means a family should ask a clinician directly whether the test can be ordered now, through which lab, and whether insurance coverage has caught up with the new age-40 clearance.
Frequently Asked Questions
Does a Positive PrecivityAD2 result confirm Alzheimer's disease by itself?
No. It indicates a high likelihood of amyloid pathology, but C2N Diagnostics specifies it should be used alongside a full clinical evaluation, not as a stand-alone diagnosis (C2N Diagnostics).
Can someone under 40 with symptoms get this test?
The FDA clearance covers adults aged 40 and older who present with signs or symptoms of cognitive impairment (Alzheimer's Association).
Why do younger-onset cases get misdiagnosed so often?
Many present with non-memory symptoms, such as visual or object-recognition problems, which clinicians are less likely to immediately connect to Alzheimer's, leading to psychiatric or other neurological misdiagnoses in over half of atypical cases in one case series (NEJM Journal Watch).
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Questions Younger-Onset Alzheimer’s Families Can Bring to a Clinician
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Questions Younger-Onset Alzheimer’s Families Can Bring to a Clinician
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Questions Younger-Onset Alzheimer’s Families Can Bring to a Clinician
